Ascendis Pharma A/SNASDAQ:ASND
- LAST PRICE127.3300
- TODAY'S CHANGE (%)-3.0800 (-2.3618%)
- Bid / Lots121.9800/ 2
- Ask / Lots171.8000/ 1
- Open / Previous Close130.7700 / 130.4100
- Day Range
- 52 Week Range
- Volume153,791
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ASND |
|---|---|---|
| 09:32 ET | 985 | 131.97 |
| 09:36 ET | 100 | 130.605 |
| 09:38 ET | 350 | 129.94 |
| 09:52 ET | 300 | 130.45 |
| 09:54 ET | 200 | 130.815 |
| 09:56 ET | 200 | 130.835 |
| 09:57 ET | 200 | 130.865 |
| 10:06 ET | 300 | 129.875 |
| 10:12 ET | 759 | 129.92 |
| 10:15 ET | 200 | 130.27 |
| 10:17 ET | 100 | 130.29 |
| 10:21 ET | 208 | 130.17 |
| 10:26 ET | 1200 | 129.42 |
| 10:33 ET | 800 | 129.07 |
| 10:35 ET | 300 | 129.53 |
| 10:39 ET | 225 | 129.645 |
| 10:46 ET | 100 | 129.39 |
| 10:48 ET | 900 | 130.12 |
| 10:50 ET | 200 | 130.26 |
| 10:51 ET | 497 | 129.99 |
| 10:53 ET | 848 | 130.215 |
| 10:55 ET | 1550 | 129.92 |
| 10:57 ET | 303 | 129.97 |
| 11:00 ET | 100 | 129.78 |
| 11:02 ET | 1206 | 128.95 |
| 11:11 ET | 600 | 128.98 |
| 11:18 ET | 1200 | 129.5244 |
| 11:20 ET | 100 | 129.5 |
| 11:22 ET | 1100 | 129.08 |
| 11:26 ET | 400 | 128.86 |
| 11:27 ET | 4877 | 128.04 |
| 11:31 ET | 498 | 128.081 |
| 11:36 ET | 100 | 128.34 |
| 11:38 ET | 100 | 128.325 |
| 11:40 ET | 100 | 128.07 |
| 11:42 ET | 200 | 127.765 |
| 11:49 ET | 100 | 128.09 |
| 11:54 ET | 1100 | 128.4 |
| 11:56 ET | 100 | 128.565 |
| 11:58 ET | 100 | 128.49 |
| 12:00 ET | 100 | 128.45 |
| 12:03 ET | 400 | 128.32 |
| 12:05 ET | 421 | 128.18 |
| 12:07 ET | 390 | 128.17 |
| 12:09 ET | 500 | 128.15 |
| 12:16 ET | 200 | 128.0033 |
| 12:18 ET | 377 | 128.025 |
| 12:20 ET | 100 | 127.985 |
| 12:21 ET | 300 | 127.94 |
| 12:23 ET | 100 | 127.975 |
| 12:27 ET | 100 | 128.27 |
| 12:30 ET | 200 | 127.94 |
| 12:48 ET | 200 | 127.54 |
| 12:50 ET | 100 | 127.335 |
| 12:52 ET | 100 | 127.63 |
| 12:57 ET | 100 | 127.22 |
| 01:01 ET | 300 | 127.12 |
| 01:03 ET | 100 | 126.905 |
| 01:06 ET | 170 | 126.826 |
| 01:10 ET | 800 | 127.13 |
| 01:14 ET | 100 | 127.11 |
| 01:15 ET | 317 | 126.93 |
| 01:24 ET | 250 | 126.54 |
| 01:33 ET | 200 | 126.27 |
| 01:37 ET | 100 | 126.5 |
| 01:39 ET | 100 | 126.33 |
| 01:44 ET | 200 | 125.96 |
| 01:46 ET | 100 | 125.99 |
| 01:51 ET | 100 | 125.87 |
| 01:53 ET | 107 | 125.885 |
| 02:00 ET | 100 | 126.3 |
| 02:04 ET | 1113 | 126.4 |
| 02:06 ET | 100 | 126.65 |
| 02:08 ET | 100 | 126.565 |
| 02:09 ET | 400 | 126.52 |
| 02:13 ET | 900 | 126.77 |
| 02:20 ET | 173 | 126.87 |
| 02:22 ET | 100 | 126.89 |
| 02:27 ET | 100 | 127.045 |
| 02:29 ET | 100 | 126.92 |
| 02:31 ET | 281 | 127.01 |
| 02:33 ET | 944 | 127.135 |
| 02:36 ET | 116 | 127.13 |
| 02:38 ET | 616 | 127.015 |
| 02:40 ET | 100 | 127.04 |
| 02:42 ET | 2100 | 127.04 |
| 02:44 ET | 700 | 127.21 |
| 02:45 ET | 1318 | 127.69 |
| 02:47 ET | 100 | 127.69 |
| 02:51 ET | 500 | 127.48 |
| 02:54 ET | 600 | 127.28 |
| 03:02 ET | 600 | 127.48 |
| 03:03 ET | 100 | 127.49 |
| 03:05 ET | 1516 | 127.505 |
| 03:12 ET | 1400 | 127.6 |
| 03:14 ET | 1200 | 127.77 |
| 03:16 ET | 206 | 127.665 |
| 03:20 ET | 100 | 127.74 |
| 03:21 ET | 2000 | 127.88 |
| 03:23 ET | 300 | 127.9 |
| 03:25 ET | 332 | 127.975 |
| 03:27 ET | 200 | 127.925 |
| 03:30 ET | 2713 | 127.935 |
| 03:36 ET | 582 | 128.19 |
| 03:39 ET | 100 | 127.92 |
| 03:41 ET | 802 | 127.94 |
| 03:48 ET | 100 | 128.11 |
| 03:50 ET | 781 | 127.805 |
| 03:52 ET | 300 | 127.53 |
| 03:54 ET | 2215 | 127.44 |
| 03:56 ET | 1579 | 127.165 |
| 03:57 ET | 2837 | 127.16 |
| 03:59 ET | 17233 | 127.33 |
May 16, 2024
DJ Ascendis Pharma Is Maintained at Equal-Weight by Morgan Stanley, from 12:11PM ET on Thursday May 16, 2024 by Dow Jones
12:11PM ET on Thursday May 16, 2024 by Dow Jones
May 15, 2024
DJ Ascendis Pharma Price Target Maintained With a $173.00/Share by Cantor Fitzgerald, from 8:37AM ET on Wednesday May 15, 2024 by Dow Jones
8:37AM ET on Wednesday May 15, 2024 by Dow Jones
May 14, 2024
DJ Ascendis Pharma Says FDA Extending Review Period for NDA, from 2:56PM ET on Tuesday May 14, 2024 by Dow Jones
2:56PM ET on Tuesday May 14, 2024 by Dow JonesAscendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon(TM) PTH for Adults with Hypoparathyroidism, from 2:31PM ET on Tuesday May 14, 2024 by Dow Jones
2:31PM ET on Tuesday May 14, 2024 by Dow Jones
May 13, 2024
Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon(TM) PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway Trial, from 8:30AM ET on Monday May 13, 2024 by Dow Jones
8:30AM ET on Monday May 13, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Ascendis Pharma A/S | 7.6B | -13.2x | --- |
Legend Biotech Corp | 7.5B | -16.0x | --- |
Blueprint Medicines Corp | 6.4B | -21.2x | --- |
Intra-Cellular Therapies Inc | 6.9B | -56.9x | --- |
Cerevel Therapeutics Holdings Inc | 7.5B | -15.1x | --- |
Vaxcyte Inc | 7.5B | -16.3x | --- |
Company Information
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
Contact Information
- Headquarters
- Tuborg Boulevard 12HELLERUP, Denmark 2900
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Albert Cha
- President, Chief Executive Officer, Executive Director, Member of the Executive Board
- Jan Moller Mikkelsen
- Chief Financial Officer, Executive Vice President, Member of the Executive Board
- Scott Smith
- Executive Vice President, Chief Administrative Officer
- Lotte Soenderbjerg
- Executive Vice President, Global Chief Commercial Officer
- Camilla Hartvig
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $7.6B |
|---|---|
Revenue (TTM) | $357.3M |
Shares Outstanding | 58.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.58 |
EPS | $-9.64 |
Book Value | $-2.74 |
P/E Ratio | -13.2x |
Price/Sales (TTM) | 21.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -109.72% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
